drug
apremilast ER
Marketedupdated 5mo agoby $AMGN AMGEN INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugOTEZLA31 co-mentions · 17 sources
- tagApproval28 co-mentions · 14 sources
- drugapremilast17 co-mentions · 17 sources
- company$AMGNAMGEN INC14 co-mentions · 14 sources
- tagSmall Molecule14 co-mentions · 14 sources
- companyUniversity of Colorado Denver1 co-mentions · 1 sources
- companyUniversity of California Los Angeles1 co-mentions · 1 sources
- companyUniversity of Virginia1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying apremilast ER
- phase4Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
- phase3A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
- phase3A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
- phase3A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
- phase3A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
- phase3HPP737 in Adult Patients With Plaque Psoriasis
- phase3Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
- phase3A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that